Petr Svoboda

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Autophagy inhibition in early but not in later stages prevents 3T3-L1 differentiation: Effect on mitochondrial remodeling

Vojtěch Škop, Monika Cahová, Helena Daňková et al. · Differentiation · 2014 · 45 citations

Cell Autophagy, Mitophagy, Mitochondrial Remodeling +8

Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle–dependent in mammalian cells, and its inhibition slows cell growth

Petr Svoboda, E Krízová, Šárka Šestáková et al. · Journal of Biological Chemistry · 2019 · 33 citations · Full text

Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress

Jaroslava Trnovská, Petr Svoboda, Helena Pelantová et al. · International Journal of Molecular Sciences · 2021 · 33 citations · Full text

Metabolic Disorder, Lipid Peroxidation, Fatty Liver Disease +22